FEATURED EDITORIAL
Realizing the therapeutic potential of miRNAs in liver disease requires confronting a problem the field has not fully reckoned with.
- Hope For Non-Hallucinogenic Neuroplastogens
- The Future Of Kidney Disease Therapeutics: Bringing Nanomedicine To Nephrology
- Injecting Cancer Killers: Intratumoral Therapy For Solid Tumors
- The Advantages Of Antibodies Over Ligands In The Alpha Emitter Era
- Proteomics Tools: A Resurrection
- Video Spotlight: Harvard's Alice Stanton On Engineering Integrated Human-Derived miBrain Organoid Models
- Elusive Success Of CDK2: Why That May Be Changing
FEATURED APPLICATION CONTENT
-
Explore how leveraging expert CDMO partnerships can streamline the development process and enhance the efficacy of your bispecific antibody therapies.
-
Consider this alternative immunization approach — the PentaMice platform, a collection of five wildtype mouse strains bred in-house for increased MHC class II diversity — and how we're leveraging it for COVID-19 antibody discovery.
-
By forging strategic partnerships with comprehensive CDMOs, see how emerging biopharma firms can navigate through early-phase development and ensure a smooth transition to clinical advancement.
-
Explore how advanced single‑cell analysis links CAR localization, cell structure, and functional behavior, offering deeper insight into CAR T cell heterogeneity and performance.
-
Gain insight into automating DNA size selection that shows how optimized bead ratios and programmable handling improve fragment recovery, consistency, and throughput.
-
Gain insight into an automated high‑input workflow that streamlines long‑read whole‑genome library prep, supporting large DNA fragments while reducing reagent use.
-
A streamlined workflow reduces reagent use and hands‑on time while preserving long‑read sequencing quality. See how multiplexed offer an efficient option for scaling or mobilizing sequencing efforts.
-
Understanding covalent warhead kinetics is key to reducing safety risks early in discovery. Learn about a new approach to GSH‑based measurements that offers clearer predictors of toxicity.
-
See how a rapid digital PCR workflow enables reliable detection of trace RCL levels while maintaining strong performance in complex samples, which support more confident decisions in manufacturing.
-
Discover how mixed-mode chromatography enables high-yield purification of single-domain antibodies under mild conditions and why these approaches outperform traditional resins.
-
Scalable lentiviral vector production is moving beyond adherent systems. Learn how streamlined workflows enable linear scale-up in stirred-tank bioreactors for cost-effective gene therapy manufacturing.
-
Decoding immune cell interactions reveals critical insights for cancer therapy. Advanced imaging and spectral analysis enable precise identification of synapses, accelerating immuno-oncology research.
- Video Spotlight: Harvard's Alice Stanton On Engineering Integrated Human-Derived miBrain Organoid Models
- Insights From The Non-Opioid Pain Therapeutics Summit: Human-Centric Translational Models And The Reawakening Of Pain Pipelines
- Schrödinger's Equation Turns 100: How Quantum Chemistry Is Improving Drug Discovery
- Annual Reflections And Predictions From The Editors' Roundtable
- The Unlikely Weapon Against Fentanyl: Your Immune System
FEATURED NEWS HEADLINES
- Curatis And Neupharma Announce Exclusive Licensing Agreement To Develop And Market Corticorelin (C-PTBE-01) For The Treatment Of Peritumoral Brain Edema In Japan
- Eledon Pharmaceuticals Announces Orphan Drug Designation Granted To Tegoprubart For The Prevention Of Allograft Rejection In Liver Transplantation
- Mining The Dark Transcriptome: U Of T Engineering Researchers Create The First Potential Drug Molecules From Long Noncoding RNA
- AI Tool Streamlines Drug Synthesis
- Mineralys Therapeutics Announces FDA Acceptance Of NDA For Lorundrostat For Treatment Of Adults With Hypertension And Topline Explore-OSA Trial Results
- GENFIT Receives FDA Orphan Drug Designation For NTZ For The Treatment Of ACLF
- Harbour BioMed And Kelun-Biotech Announce NMPA Approval Of IND Application For HBM7575/SKB575 For The Treatment Of Atopic Dermatitis
- Precision BioSciences Receives FDA Fast Track Designation For PBGENE-DMD And Announces Duchenne Muscular Dystrophy Investor Event
- New Approach To Drug Development
- GNTbm's Self-Developed Anti-Cancer New Drug GNTbm-38 Has Obtained IND Approval From The U.S. FDA For Phase I Clinical Trials
ARCHIVED NEWSLETTER
- 03.07.26 -- Drug Discovery Online Best Of February
- 03.03.26 -- In Vivo LNP-Engineered Cytokine-Armored CAR Cells For Solid Tumors
- 02.24.26 -- Small Molecule Enzyme Mimetics In Age-Related Neurodegeneration
- 02.17.26 -- Avoiding Protein Purification Artifacts That Still Undermine Drug Design
- 02.10.26 -- Designing Drugs For Women: Closing The Therapeutic Gap